Equillium, Inc. (EQ) stock
EQNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.32−0.10 (-7.04%)
Close on Nov 12, 2026Market cap $83.70MP/E –Yield –
Equillium EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Equillium's EPS for the twelve months ending Sep 30, 2025 was -$0.62. For fiscal 2025 it was -$0.39. The highest annual figure on record is -$0.23 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.39 | – |
| FY2024 | Dec 31, 2024 | -$0.23 | – |
| FY2023 | Dec 31, 2023 | -$0.38 | – |
| FY2022 | Dec 31, 2022 | -$1.85 | – |
| FY2021 | Dec 31, 2021 | -$1.36 | – |
| FY2020 | Dec 31, 2020 | -$1.46 | – |
| FY2019 | Dec 31, 2019 | -$1.47 | – |
| FY2018 | Dec 31, 2018 | -$1.09 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.04 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.04 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.06 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.06 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.16 | -1700.0% |
| Q1 FY2025 | Mar 31, 2025 | -$0.24 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.16 | – |
| Q3 FY2024 | Sep 30, 2024 | $0.00 | – |
| Q2 FY2024 | Jun 30, 2024 | $0.01 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.08 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.07 | -187.5% |
| Q3 FY2023 | Sep 30, 2023 | -$0.11 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.10 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.11 | – |
| Q4 FY2022 | Dec 31, 2022 | $0.08 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.40 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.41 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.17 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.36 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.35 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.31 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.33 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.36 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.31 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.37 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.45 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.44 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.35 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.35 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.34 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.31 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.44 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.16 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.15 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.10 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.01 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.10 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?